Cynthia LaCivita

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research, University of the Potomac

Pharmacology, Toxicology and PharmaceuticsMedicineEconomics, Econometrics and FinanceMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020”.

Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020

Drug Safety(2024)10.1007/s40264-024-01443-3

N/A

0DataRank · unranked

6 citations

Ameet Sarpatwari, Krista F. Huybrechts, Joyce Lii, Su Been Lee, Gita A. Toyserkani +6 more

Prescription Drugs Subject to a Risk Evaluation and Mitigation Strategy: Patient Perspectives on Risk Communication and the Value of Educational Materials

Drug Safety(2025)10.1007/s40264-025-01636-4

N/A

0DataRank · unranked

0 citations

Carol Cosenza, Aaron S. Kesselheim, Gita A. Toyserkani, Kate Heinrich Oswell, Cynthia LaCivita +3 more